Oppenheimer Asset Management Inc. Invests $49.62 Million in CVS Health Corporation $CVS

Oppenheimer Asset Management Inc. acquired a new stake in shares of CVS Health Corporation (NYSE:CVS) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 479,674 shares of the pharmacy operator’s stock, valued at approximately $49,622,000.

Several other hedge funds have also made changes to their positions in the stock. Beaird Harris Wealth Management LLC grew its position in CVS Health by 201.0% during the second quarter. Beaird Harris Wealth Management LLC now owns 292 shares of the pharmacy operator’s stock worth $30,000 after buying an additional 195 shares in the last quarter. Swiss RE Ltd. acquired a new position in CVS Health in the 4th quarter valued at approximately $26,000. Sankala Group LLC bought a new stake in shares of CVS Health in the 4th quarter worth approximately $28,000. Caitong International Asset Management Co. Ltd grew its holdings in shares of CVS Health by 407.2% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after purchasing an additional 281 shares in the last quarter. Finally, Mcguire Capital Advisors Inc. bought a new stake in shares of CVS Health during the fourth quarter valued at approximately $28,000. Institutional investors own 80.66% of the company’s stock.

Insider Transactions at CVS Health

In related news, Director Larry Robbins sold 1,983,538 shares of CVS Health stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the completion of the transaction, the director directly owned 6,213,261 shares of the company’s stock, valued at $586,842,501.45. This trade represents a 24.20% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last ninety days, insiders have sold 3,372,000 shares of company stock worth $317,473,598. Company insiders own 0.85% of the company’s stock.

CVS Health Price Performance

Shares of CVS stock opened at $97.09 on Friday. The stock’s fifty day simple moving average is $102.52 and its 200 day simple moving average is $88.23. CVS Health Corporation has a one year low of $67.42 and a one year high of $110.68. The firm has a market cap of $124.18 billion, a price-to-earnings ratio of 25.69, a P/E/G ratio of 0.91 and a beta of 0.61. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.87 and a quick ratio of 0.66.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.87 by $0.71. The firm had revenue of $106.10 billion during the quarter, compared to analyst estimates of $100.03 billion. CVS Health had a return on equity of 13.12% and a net margin of 1.18%.The business’s revenue for the quarter was up 7.3% compared to the same quarter last year. During the same period in the prior year, the company posted $1.81 earnings per share. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, analysts expect that CVS Health Corporation will post 8.02 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 23rd were given a dividend of $0.665 per share. The ex-dividend date was Thursday, July 23rd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.7%. CVS Health’s dividend payout ratio (DPR) is 70.37%.

Analyst Upgrades and Downgrades

CVS has been the subject of several research reports. Mizuho raised their target price on CVS Health from $110.00 to $115.00 and gave the stock an “outperform” rating in a research report on Monday, June 8th. Bank of America boosted their price target on shares of CVS Health from $100.00 to $110.00 and gave the company a “buy” rating in a report on Monday, June 22nd. Wells Fargo & Company increased their price objective on shares of CVS Health from $103.00 to $123.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. Royal Bank Of Canada lifted their target price on shares of CVS Health from $107.00 to $113.00 and gave the company an “outperform” rating in a research report on Thursday, July 9th. Finally, Wall Street Zen raised shares of CVS Health from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Twenty-two investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $106.75.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.